

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/876,348	06/07/2001	Kathleen L. Horwath	RB-125 RI	9095	
7590 12:03/2003			EXAM	EXAMINER	
Mark Levy			ROBINSON, HOPE A		
SALZMAŇ & LEVY Stc. 902			ART UNIT	PAPER NUMBER	
19 Chenango St.			1653		
Binghamton, N	IY 13901		DATE MAILED: 12/03/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

- 		Application No.	Applicant(s)
		09/876,348	HORWATH ET AL.
Office Action Summary		Examin r	Art Unit
		Hope A. Robinson	1653
Period fo		nication appears on the cover sheet wit	th the correspondence address
THE I - Externafter - If the - If NO - Failu - Any I	MAILING DATE OF THIS COMMUN nsions of time may be available under the provision SIX (6) MONTHS from the mailing date of this come period for reply specified above is less than thirty (6) period for reply is specified above, the maximum is the toreply within the set or extended period for reply within the set or extended period for reply.	ns of 37 CFR 1.136(a). In no event, however, may a re	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
1)🖂	Responsive to communication(s) f	filed on <u>26 September 2003</u> .	
2a) <u></u>	This action is FINAL .	2b)⊠ This action is non-final.	
3)□ Dispositi		on for allowance except for formal maticitice under Ex parte Quayle, 1935 C.E	
·	Claim(s) 1-34 is/are pending in the	application.	
•	· · · · · -	is/are withdrawn from consideration.	
	Claim(s) is/are allowed.		
·	Claim(s) <u>1-32</u> is/are rejected.		
	Claim(s) is/are objected to.		
	Claim(s) are subject to restri	iction and/or election requirement.	
,	on Papers	,	
9)🛛	The specification is objected to by the	ne Examiner.	
10)[The drawing(s) filed on is/are	e: a) ☐ accepted or b) ☐ objected to by th	ne Examiner.
	Applicant may not request that any ob-	ojection to the drawing(s) be held in abeya	ince. See 37 CFR 1.85(a).
11)[The proposed drawing correction file	ed on is: a)□ approved b)□ di	isapproved by the Examiner.
	If approved, corrected drawings are re	equired in reply to this Office action.	
12) 🗌	The oath or declaration is objected t	o by the Examiner.	
Priority L	ınder 35 U.S.C. §§ 119 and 120		
13)[Acknowledgment is made of a claim	n for foreign priority under 35 U.S.C. §	3 119(a)-(d) or (f).
a)[☐ All b)☐ Some * c)☐ None of:		
	1. Certified copies of the priority	y documents have been received.	
	2. Certified copies of the priority	y documents have been received in Ap	oplication No
* S	application from the Inter	of the priority documents have been in national Bureau (PCT Rule 17.2(a)). on for a list of the certified copies not r	_
		for domestic priority under 35 U.S.C. §	
	• • • • • • • • • • • • • • • • • • • •	inguage provisional application has be for domestic priority under 35 U.S.C.	
Attachmen	•	, , , , , , , , , , , , , , , , , , , ,	
1) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (nation Disclosure Statement(s) (PTO-1449) F	PTO-948) 5) Notice of Ir	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152)

DETAILED ACTION

1. Applicant's election with traverse filed on September 26, 2003 of Group I (claims 1-32) is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Abstract

2. The abstract is objected to because the word "said" is used in the last line.

Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

Correction is required.

Application/Control Number: 09/876,348 Page 3

Art Unit: 1653

Specification

3. The specification is objected to because of the following informalities:

The specification is objected to because on page 145 there appears the following hyperlink (www.ncbi.nlm.nih.gov).

Correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 1-32 are rejected under 112, second paragraph as failing to distinctly point out the subject matter applicant regards as his invention.

Claim 1 is indefinite for the recitation of "relative concentration" as the term is not defined in the claim or the specification. As the specification does not provide a standard for ascertaining the requisite concentration, one of ordinary skill in the art would not be reasonably appraised of the invention as claimed (see also claim 25 which uses the term "relative"). The claim should set forth the concentration amount. The claim is also indefinite as to the phrase "and/or" because it is unclear if the slash mark represents "and", "or" or "and or". The claim is further indefinite as the recrystallization inhibition is unclear as to what is being recrystallized. It is thought that ice recrystallization is what's inhibited. Claim 1 is indefinite as to determining the presence, relative concentration and activity of thermal hysteresis proteins because it appears the

Art Unit: 1653

present method is refers to ice crystal formation especially since the last step is a mental interpretation and not a physical step *per se* and does not correlate ice crystal grain size with "presence, relative concentration and/or activity". Step 1 of the method is indefinite because does not recite that the proteinaceous composition is thermal hysteresis the protein recited in the preamble and in view of claim 4. The dependent claims hereto are also included in this rejection.

Claim 2 is indefinite for the recitation of "or other isoosmotic inorganic or organic solutions" as this is open ended and undefined.

Claim 3 is indefinite and lacks antecedent basis because the claim recites two or more control solutions and lists a "solvent and a control for a non-specific recrystallization inhibition effects" and the later is not a solution *per se*.

Claim 4 lacks antecedent basis as it depends from claim 1 which recites "determining the presence, relative concentration and/or activity of thermal hysteresis proteins" and claim 4 requires that the activity of the protein is known. The dependent claims here to are also included.

Claim 6 provides a Markush listing of "proteinaceous compositions which are inconsistent with the preamble of independent claim 1, see for example in claim 6,"cell culture products, uncharacterized plant products etc., when the method is geared towards determining presence/activity/concentration of a thermal hysteresis protein.

Claim 7 is indefinite as to "unknown functional antifreeze protein activity". How is what is stated as unknown assessed in the claim?

Art Unit: 1653

Claim 8 lacks antecedent basis as the claim recites "said protein composition of Tm 12.86 is 0.5ug to 25 ug/ml" and claim 4 only recites "proteinaceous composition".

Claim 9 lacks antecedent basis for the recitation of "said protein content is less than or equal to 1mg/ml..." as this is not recited in claim 2.

Claim 19 is indefinite for "[arcsine[(mlgs)0.2] verses log(dilution)]" with respect to brackets in the claim and the inconsistency of the type of brackets.

Claim 26 is indefinite with respect to "known characterized parameters experimentally measured", as the metes and bounds of the claim are undefined as to what parameters and how measured. Known to whom? (see also claims 4, 27).

Claim 29 is indefinite as the claim is missing a transitional phrase see where it recites "...are described by equation..." instead of " ...are described by the equation...".

Claim 30 is indefinite because the term "high annealing temperature" is a relative term. The term high temperature is not defined by the claim or the specification as no standards are provided to delineate the requisite degree.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.

Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1653

- 5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C 103(a).
- 6. Claim 1 is rejected under 35 U.S.C. 103(a) as unpatentable over Olien (Ann. Rev. Plant Physiology, vol. 18, pages 337-408, 1967) in view of Warren et al. (U.S. Patent No. 5,118,792).

Olien disclose plants that survived the thermal stress of freezing and used the plant extracts (proteinaceous composition) to test for antifreeze properties. The method used by Olien involves monitoring the thermodynamics and kinetics of ice crystal growth in a film during a refreezing process in the presence and absence of the test extract (page 396). In addition, freezing is performed followed by thawing about three fourths (partial thaw), then the sample is then refrozen slowly. This is a measure of recrystallization inhibition. Freezing is also performed followed by thawing about three fourths, then the sample is then refrozen rapidly. This is a form of monitoring thermal hysteresis. Olien does not explicitly teach a method for determining the presence of the

Art Unit: 1653

hysteresis protein, however, the activity is monitored. Here, Warren et al. disclose screening antifreeze polypeptides by monitoring inhibition of ice crystal growth via refreezing on a cooled metal block, the splat assay (column 4, lines 48-62 and example 3).

One of skill in the art at the time the invention was made would have been motivated to use the method for monitoring antifreeze properties such as those taught by Olien or Warren et al. because a person of skill in the art would reasonably use available tools to monitor such processes. Additionally, Warren et al. provide motivation to find antifreeze proteins in an organism that exhibits freeze tolerance, to mitigate the damages associated with recrystallization. Hence it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to use any available method to screen for antifreeze proteins.

Conclusion

7. No claims are allowable.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Hope A. Robinson whose telephone number is (703)308-6231. The Examiner can normally be reached on Monday - Friday from 9:00 A.M. to 6:30 P.M. (EST).

Art Unit: 1653

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's

supervisor Christopher S. F. Low, can be reached at (703)308-2923.

Any inquiries of a general nature relating to this application should be directed to

the Group Receptionist whose telephone number is (703)308-0196.

Papers related to this application may be submitted by facsimile transmission.

The official fax phone number for Technology Center 1600 is (703) 308-4242. Please

affix the Examiner's name on a cover sheet attached to your communication should you

choose to fax your response. The faxing of such papers must conform with the notice

published in the Official Gazette, 1096 OG (November 15, 1989).

Hope A. Robinson, MS

Page 8

Patent Examiner

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600